Metformin and Longevity: The TAME Trial and Anti-Aging Research Evidence

A Diabetes Drug Taken by 120 Million People May Also Slow Biological Aging

Metformin has been prescribed for type 2 diabetes for over 60 years and is among the most widely used medications on earth. But since the early 2010s, a growing body of epidemiological evidence suggested something unexpected: diabetic patients on metformin were not just controlling their blood sugar — they were outliving non-diabetics not taking the drug. A 2014 observational study published in Diabetes, Obesity and Metabolism found that metformin users with type 2 diabetes had a 15% lower all-cause mortality than matched non-diabetics on no medication. That finding launched a scientific debate that culminated in the Targeting Aging with Metformin (TAME) trial — the first randomized controlled trial in history explicitly designed to use a drug to delay aging itself as a primary endpoint.

What TAME Is Testing

The TAME trial, funded by the American Federation for Aging Research (AFAR) and initiated in 2023, is enrolling approximately 3,000 participants aged 65–79 across 14 U.S. research sites. Participants receive either metformin 1,500 mg daily or placebo, with a projected follow-up of 6 years. The primary endpoint is not any single disease — it is a composite outcome capturing the first occurrence of any of several age-related conditions: cardiovascular disease, cancer, dementia, and death. This composite approach reflects the geroscience hypothesis that aging itself is the shared root cause of these diseases. If metformin can delay the composite endpoint, it would constitute the first proof-of-concept that a pharmacological agent can target the aging process in humans.

Proposed Mechanisms

Metformin's anti-aging mechanisms are multiple and partially overlapping. None is fully proven in humans, but all have supporting laboratory or animal evidence.

• AMPK activation: Metformin activates AMP-activated protein kinase (AMPK), a cellular energy sensor that promotes metabolic efficiency, mitophagy (clearance of damaged mitochondria), and autophagy — the cellular "self-cleaning" process that declines with age
• mTOR inhibition: Indirectly suppresses the mTORC1 signaling pathway, whose chronic overactivation is associated with accelerated aging across model organisms
• Reduction of mitochondrial complex I: Mildly inhibits the mitochondrial electron transport chain, which paradoxically reduces damaging reactive oxygen species production by forcing more efficient energy use
• Gut microbiome modulation: Alters the composition of intestinal bacteria in ways associated with reduced metabolic inflammation
• Epigenetic effects: Some evidence suggests metformin slows the "epigenetic clock" — methylation patterns in DNA that track biological age with reasonable accuracy

What Observational Data Shows

The Cancer Connection

Beyond cardiovascular aging, metformin has attracted sustained interest for cancer prevention and adjuvant treatment. Multiple epidemiological studies show 20–40% reduced incidence of colorectal, breast, prostate, and endometrial cancers in metformin users. The proposed mechanisms — AMPK activation reducing cellular proliferation signals, mTOR inhibition slowing tumor growth, and reduction of hyperinsulinemia (a known cancer promoter) — are biologically plausible. However, randomized controlled trials testing metformin as an adjuvant cancer therapy have produced mixed results, and systematic reviews conclude that the evidence remains insufficient to recommend metformin for cancer prevention in non-diabetics. Several trials are ongoing.

Safety Profile: Why This Matters for Healthy People

If TAME results are positive, metformin would be prescribed to healthy people aging normally — a very different population from the drug's current users. The safety context is therefore critical.

• Lactic acidosis: The drug's most serious risk is lactic acidosis — but incidence is approximately 3 per 100,000 person-years and mainly affects patients with impaired kidney function. Metformin is contraindicated in severe CKD (eGFR < 30 mL/min/1.73 m²).
• Vitamin B12 depletion: Long-term metformin use reduces B12 absorption in 10–30% of users. Peripheral neuropathy from B12 deficiency is a genuine risk; supplementation or monitoring is recommended after 4+ years of use.
• GI side effects: Nausea, diarrhea, and abdominal discomfort affect 20–30% of initiators; extended-release formulation significantly reduces incidence
• Exercise performance: Two randomized trials found metformin blunted the cardiovascular fitness gains from aerobic exercise training — a concern for active individuals that TAME researchers are actively studying

What Scientists Are Cautious About

Some aging researchers argue that TAME's composite endpoint design, while scientifically creative, makes it difficult to conclude that metformin is truly targeting aging rather than just preventing individual diseases through known anti-diabetic effects. Others note that the AMPK/mTOR pathway targeted by metformin also responds to caloric restriction and exercise — raising the possibility that the drug's benefits are mechanistically redundant with lifestyle interventions that carry fewer risks for healthy, active older adults. A definitive answer awaits TAME's completion, projected around 2029–2030.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.